お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:鬱病・不安障害:医薬品開発パイプライン分析
市場調査レポート
商品コード
716082

鬱病・不安障害:医薬品開発パイプライン分析

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018

出版日: | 発行: GlobalData | ページ情報: 英文 175 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.93円
鬱病・不安障害:医薬品開発パイプライン分析
出版日: 2018年09月21日
発行: GlobalData
ページ情報: 英文 175 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、鬱病・不安障害 (心的外傷後ストレス障害 (PTSD)、強迫神経症 (OCD)、鬱病) 治療薬について調査分析し、パイプライン情勢の概要、開発中の治療薬、関与している主要企業、開発が休止・中止された製品など、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 治療薬の開発

  • 心的外傷後ストレス障害 (PTSD)
  • 強迫神経症 (OCD)
  • 鬱病

第4章 治療薬の評価

  • 心的外傷後ストレス障害 (PTSD)
  • 強迫神経症 (OCD)
  • 鬱病

第5章 治療薬の開発に従事している企業

  • 心的外傷後ストレス障害 (PTSD)
  • 強迫神経症 (OCD)
  • 鬱病

第6章 休止中のプロジェクト

  • 心的外傷後ストレス障害 (PTSD)
  • 強迫神経症 (OCD)
  • 鬱病

第7章 開発が中止された製品

  • 心的外傷後ストレス障害 (PTSD)
  • 強迫神経症 (OCD)
  • 鬱病

第8章 製品開発のマイルストーン

  • 心的外傷後ストレス障害 (PTSD)
  • 強迫神経症 (OCD)
  • 鬱病

第9章 付録

図表

List of Tables

  • Table 1: Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) 10
  • Table 2: Number of Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 12
  • Table 3: Number of Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 13
  • Table 4: Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 14
  • Table 5: Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 16
  • Table 6: Number of Products under Development for Obsessive-Compulsive Disorder 17
  • Table 7: Number of Products under Development by Companies, Obsessive-Compulsive Disorder 18
  • Table 8: Number of Products under Development by Universities/Institutes, Obsessive-Compulsive Disorder 19
  • Table 9: Products under Development by Companies, Obsessive-Compulsive Disorder 19
  • Table 10: Products under Development by Universities/Institutes, Obsessive-Compulsive Disorder 19
  • Table 11: Number of Products under Development for Depression 20
  • Table 12: Number of Products under Development by Companies, Depression 22
  • Table 13: Number of Products under Development by Universities/Institutes, Depression 27
  • Table 14: Products under Development by Companies, Depression 28
  • Table 15: Products under Development by Universities/Institutes, Depression 39
  • Table 16: Number of Products by Stage and Target, Post-Traumatic Stress Disorder (PTSD) 42
  • Table 17: Number of Products by Stage and Mechanism of Action, Post-Traumatic Stress Disorder (PTSD) 45
  • Table 18: Number of Products by Stage and Route of Administration, Post-Traumatic Stress Disorder (PTSD) 47
  • Table 19: Number of Products by Stage and Molecule Type, Post-Traumatic Stress Disorder (PTSD) 49
  • Table 20: Number of Products by Stage and Target, Obsessive-Compulsive Disorder 50
  • Table 21: Number of Products by Stage and Mechanism of Action, Obsessive-Compulsive Disorder 52
  • Table 22: Number of Products by Stage and Route of Administration, Obsessive-Compulsive Disorder 53
  • Table 23: Number of Products by Stage and Molecule Type, Obsessive-Compulsive Disorder 53
  • Table 24: Number of Products by Stage and Target, Depression 55
  • Table 25: Number of Products by Stage and Mechanism of Action, Depression 60
  • Table 26: Number of Products by Stage and Route of Administration, Depression 65
  • Table 27: Number of Products by Stage and Molecule Type, Depression 67
  • Table 28: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd 68
  • Table 29: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd 69
  • Table 30: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc 69
  • Table 31: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc 69
  • Table 32: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc 70
  • Table 33: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd 70
  • Table 34: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc 71
  • Table 35: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd 71
  • Table 36: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc 72
  • Table 37: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co 72
  • Table 38: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc 73
  • Table 39: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd 73
  • Table 40: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson 74
  • Table 41: Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc 74
  • Table 42: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp 75
  • Table 43: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd 76
  • Table 44: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics SAS 76
  • Table 45: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi 76
  • Table 46: Post-Traumatic Stress Disorder (PTSD) - Pipeline by SpringWorks Therapeutics LLC 77
  • Table 47: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp 77
  • Table 48: Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd 78
  • Table 49: Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc 78
  • Table 50: Obsessive-Compulsive Disorder - Pipeline by Biohaven Pharmaceutical Holding Company Ltd 79
  • Table 51: Obsessive-Compulsive Disorder - Pipeline by Omeros Corp 79

List of Figures

  • Figure 1: Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) 10
  • Figure 2: Number of Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 11
  • Figure 3: Number of Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 13
  • Figure 4: Number of Products under Development for Obsessive-Compulsive Disorder 17
  • Figure 5: Number of Products under Development by Companies, Obsessive-Compulsive Disorder 18
  • Figure 6: Number of Products under Development for Depression 20
  • Figure 7: Number of Products under Development by Companies, Depression 21
  • Figure 8: Number of Products under Development by Universities/Institutes, Depression 26
  • Figure 9: Number of Products by Top 10 Targets, Post-Traumatic Stress Disorder (PTSD) 41
  • Figure 10: Number of Products by Stage and Top 10 Targets, Post-Traumatic Stress Disorder (PTSD) 41
  • Figure 11: Number of Products by Top 10 Mechanism of Actions, Post-Traumatic Stress Disorder (PTSD) 43
  • Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Post-Traumatic Stress Disorder (PTSD) 44
  • Figure 13: Number of Products by Routes of Administration, Post-Traumatic Stress Disorder (PTSD) 46
  • Figure 14: Number of Products by Stage and Routes of Administration, Post-Traumatic Stress Disorder (PTSD) 47
  • Figure 15: Number of Products by Molecule Types, Post-Traumatic Stress Disorder (PTSD) 48
  • Figure 16: Number of Products by Stage and Molecule Types, Post-Traumatic Stress Disorder (PTSD) 48
  • Figure 17: Number of Products by Top 10 Targets, Obsessive-Compulsive Disorder 49
  • Figure 18: Number of Products by Stage and Top 10 Targets, Obsessive-Compulsive Disorder 50
  • Figure 19: Number of Products by Top 10 Mechanism of Actions, Obsessive-Compulsive Disorder 51
  • Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, Obsessive-Compulsive Disorder 51
  • Figure 21: Number of Products by Stage and Routes of Administration, Obsessive-Compulsive Disorder 52
  • Figure 22: Number of Products by Stage and Top 10 Molecule Types, Obsessive-Compulsive Disorder 53
  • Figure 23: Number of Products by Top 10 Targets, Depression 54
  • Figure 24: Number of Products by Stage and Top 10 Targets, Depression 54
  • Figure 25: Number of Products by Top 10 Mechanism of Actions, Depression 59
  • Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions, Depression 59
  • Figure 27: Number of Products by Routes of Administration, Depression 64
  • Figure 28: Number of Products by Stage and Routes of Administration, Depression 65
  • Figure 29: Number of Products by Molecule Types, Depression 66
  • Figure 30: Number of Products by Stage and Molecule Types, Depression 66
目次
Product Code: GBIHC045IDB

Abstract

  • Depression and Anxiety Disorders Drug Development Pipeline Review, 2018
  • Summary
  • PTSD is a mental health condition that is triggered by either experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants and cognitive therapy. There are 38 products in development for this indication.
  • OCD is characterized by unreasonable thoughts and fears (obsessions) that lead to repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again.
  • Treatment includes antidepressants and psychiatric medications. There are nine products in development for this indication.
  • Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches.
  • Treatment includes antidepressants, mood stabilizers and antipsychotics. There are 212 products in development for this indication.
  • Molecular targets acted on by products in development for depression and anxiety disorders include neurotransmitter receptors such as glutamate receptors and 5-hydroxytryptamine receptors. Companies operating in this pipeline space include NeuroRx, Amorsa Therapeutics and Johnson & Johnson.
  • This report "Depression and Anxiety Disorders Drug Development Pipeline Review, 2018" provides an overview of the pipeline landscape for depression and anxiety disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD) and depression, and features dormant and discontinued products.
  • Scope
  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
  • Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 5
  • 1.2 List of Figures 8

2 Introduction 9

  • 2.1 Depression and Anxiety Disorders Report Coverage 9
  • 2.2 Post-Traumatic Stress Disorder (PTSD) - Overview 9
  • 2.3 Obsessive-Compulsive Disorder - Overview 9
  • 2.4 Depression - Overview 9

3 Therapeutics Development 10

  • 3.1 Post-Traumatic Stress Disorder (PTSD) 10
  • 3.2 Obsessive-Compulsive Disorder 17
  • 3.3 Depression 20

4 Therapeutics Assessment 41

  • 4.1 Post-Traumatic Stress Disorder (PTSD) 41
  • 4.2 Obsessive-Compulsive Disorder 49
  • 4.3 Depression 54

5 Companies Involved in Therapeutics Development 68

  • 5.1 Post-Traumatic Stress Disorder (PTSD) 68
  • 5.2 Obsessive-Compulsive Disorder 78
  • 5.3 Depression 80

6 Dormant Projects 122

  • 6.1 Post-Traumatic Stress Disorder (PTSD) 122
  • 6.2 Obsessive-Compulsive Disorder 124
  • 6.3 Depression 125

7 Discontinued Products 141

  • 7.1 Post-Traumatic Stress Disorder (PTSD) 141
  • 7.2 Obsessive-Compulsive Disorder 141
  • 7.3 Depression 142

8 Product Development Milestones 147

  • 8.1 Post-Traumatic Stress Disorder (PTSD) 147
  • 8.2 Obsessive-Compulsive Disorder 156
  • 8.3 Depression 157

9 Appendix 174

  • 9.1 Methodology 174
  • 9.2 Coverage 174
  • 9.3 Secondary Research 174
  • 9.4 Primary Research 174
  • 9.5 Expert Panel Validation 174
  • 9.6 Contact Us 175
  • 9.7 Disclaimer 175
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.